Volume 16, Issue 4 pp. 355-366
RESEARCH ARTICLE

Stromal cell derived factor 1 plasmid to regenerate the anal sphincters

Li Sun

Li Sun

Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Alanna Billups

Alanna Billups

Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Anna Rietsch

Anna Rietsch

Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Margot S. Damaser

Margot S. Damaser

Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA

Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Advanced Platform Technology Center, Cleveland, Ohio, USA

Search for more papers by this author
Massarat Zutshi

Corresponding Author

Massarat Zutshi

Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence

Massarat Zutshi, Department of Colorectal Surgery, Cleveland Clinic, 9500 Euclid Avenue A30, Cleveland, OH 44195, USA.

Email: [email protected]

Search for more papers by this author
First published: 29 January 2022
Citations: 1

Abstract

The aim of this study was to evaluate regeneration of a chronic large anal sphincter defect in a pig model after treatment with a plasmid encoding Stromal Cell Derived Factor-1(SDF-1).

Methods

Under ethics approved protocol 19 age/weight matched Sinclair mini-pigs were subjected to excision of the posterior 50% of anal sphincter muscle and left to recover for 6 weeks. They were randomly allocated to receive either saline treatment (Saline 1 ml, n = 5), 1 injection of SDF-1 plasmid 2 mg/ml (1 SDF-1, n = 9) or 2 injections of SDF-1, 2 mg/ml each at 2 weeks intervals (2 SDF-1, n = 5). Euthanasia occurred 8 weeks after the last treatment. In vivo outcomes included anal resting pressures done under anesthesia pre-injury, pre-injection and before euthanasia (8 weeks after treatment). Anal ultrasound was done pre injury and pre-euthanasia. Tissues were saved for histology and analyzed quantitatively. Two way ANOVA followed by Holm-Sidak test and one way ANOVA followed by the Tukey test were used for data analysis, p < 0.05 was regarded as significant.

Results

Posterior anal pressures at the 3 time points were not significantly different in the saline group. In contrast, post-treatment pressures in the 1 SDF-1 group pressures were significantly higher than both pre-injury (p = 0.001) and pre-treatment time points (p = 0.003). At the post-treatment time point, both 1 SDF-1 (p = 0.01) and 2 SDF-1 (p = 0.01) groups had significantly higher mean pressures compared to the saline group. Histology showed distortion of normal anatomy with patchy regeneration in the control group while muscle was more organized in both treatment groups.

Conclusions

Eight weeks after a single or two doses of SDF-1injected into a chronic anal sphincter injury improved resting anal pressures and regenerated muscle in the entire defect. SDF-1 plasmid is effective in treating chronic defects of the anal sphincter in a large animal and could be clinically translated.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.